[ad_1]
Industry veteran Ray Kaczmarek has recently joined Nanoscope Therapeutics as their chief technology and manufacturing officer. Nanoscope is a late-stage clinical biotechnology company focused on developing gene therapies for inherited retinal diseases and geographic atrophy. Kaczmarek is known for his expertise in gene therapy manufacturing, with years of experience in leading operations, technology, and commercial supply strategies at various pharmaceutical and biotechnology companies.
Sulagna Bhattacharya, the CEO of Nanoscope, expressed excitement about Kaczmarek’s appointment, stating that his operational leadership would be essential in developing the commercial supply of their future therapies as they move towards potential commercialization. Prior to joining Nanoscope, Kaczmarek served as the CEO of Genezen and held various leadership roles in the gene therapy manufacturing industry.
Kaczmarek expressed his enthusiasm for joining Nanoscope, highlighting the company’s mission to bring transformative gene therapy products to market. He looks forward to leading the build-out of commercial product manufacturing to ensure that Nanoscope is prepared to provide much-needed treatments to patients.
Nanoscope Therapeutics is currently developing gene-agnostic optogenetic therapies to restore sight for patients blinded by retinal degenerative diseases. Kaczmarek’s appointment comes at a pivotal juncture for the company, as they aim to bring these innovative therapies to market. With his extensive experience and leadership in gene therapy manufacturing, Kaczmarek is poised to play a crucial role in Nanoscope’s future success.
Source
Photo credit dallasinnovates.com
